【摘要】 目的:探究注射用头孢哌酮钠舒巴坦钠的应用效果及不良反应。方法:选取某院2018年4月～2019年4月期间80例接受抗感染治疗患者的临床资料进行回顾性分析,根据不同的治疗药物将患者分为参照组和研究组各40例,即应用注射用头孢他啶治疗的患者纳入参照组,而应用注射用头孢哌酮钠舒巴坦钠治疗的患者纳入研究组,记录两组临床疗效与不良反应发生率。结果:参照组、研究组总有效率分别为75.00%、97.50%,比较发现研究组总有效率更高(P<0.05);参照组、研究组不良反应发生率分别为10.00%、27.50%,比较发现研究组不良反应发生率高于参照组(P<0.05)。结论:注射用头孢哌酮钠舒巴坦钠用于抗感染治疗的临床疗效优于注射用头孢他啶,但其不良反应发生率明显较高,临床应用需根据患者病情、体质谨慎选择药物与剂量,保证患者用药安全。更多还原

【Abstract】 Objective: To explore the effects and adverse reactions of cefoperazone sodium and sulbactam sodium for injection. Methods: The clinical data of 80 patients receiving anti-infective treatment in a hospital from April 2018 to April 2019 were analyzed retrospectively. The patients were divided into two groups according to different treatment drugs.Patients treated with ceftazidime for injection were included in the reference group,and patients treated with cefoperazone sodium and sulbactam sodium for injection were included in the study group. The ratio of the two groups was 40∶40. The clinical efficacy and the incidence of adverse reactions in the two groups were recorded. Results: The total effective rate of the reference group and the study group was 75.00% and 97.50%, respectively. The comparison found that the total effective rate of the study group was higher(P<0.05). The incidence of adverse reactions in the reference group and the study group was 10.00% and 27.50%, respectively, and it was found that the incidence of adverse reactions in the study group was higher(P<0.05). Conclusion:Cefoperazone sodium sulbactam sodium for injection is superior to ceftazidime for anti-infection treatment, but the incidence of adverse reactions is significantly higher.Clinical application requires careful selection of drugs and doses according to the patient’s condition and constitution to ensure the patient’s medication safety.更多还原